• Written informed consent, signed and duly dated.

• Man or woman between 12 and 65 years old (both included).

• Patient with moderate or severe symptoms of persistent rhinitis according to the ARIA Guide, associated or not with well or partially controlled asthma according to the GEMA 5.0 Guide.

• Confirmation of sensitization to DPT or DF with a positive prick test (mean papule diameter greater than or equal to 3 mm) with a commercial standardized allergenic extract and a serum extract-specific IgE value of class 3 or higher (\> 3.5 kU / L) within the 6 months prior to the study.

• Negative pregnancy test.

• Nasal symptom and medication combined scale score ≥ 1.5 during the screening phase.